Mounjaro 2nd dose instructions: the misconception that catches people out

The myth: 'second dose' means a higher strength automatically

This is a question our prescribers hear most weeks, and it's understandable why. The phrase 'second dose' gets used in two different ways: sometimes it means the second weekly injection from your current pen, and sometimes it means the second pen in the sequence, which might carry a higher strength. Those are not the same thing, and conflating them is where people run into difficulty.

A single Mounjaro KwikPen delivers four weekly doses at the same strength. So if you started on 2.5 mg, your second, third and fourth injections all come from that same pen. The 'second dose' you're looking for instructions on is almost certainly injection number two from pen number one, and if you want a full walkthrough of that process, our Mounjaro second dose instructions cover everything step by step.

Where titration enters the picture is when you move to a new pen after exhausting the first. Your prescriber decides whether that next pen stays at 2.5 mg for another month or steps up to 5 mg. That decision is based on how you've tolerated the starter strength, not on a fixed timetable. The Mounjaro overview on this site explains the full licensed strength range in the UK if you want context on where 2.5 mg sits in the wider schedule.

Injection technique at dose two: what stays the same

The physical process of injecting your second dose is identical to the first. Choose one of the three licensed injection sites (the abdomen (avoiding the area immediately around the navel), the front or outer thigh, or the upper arm) and rotate to a different spot from the week before. Rotating within and between sites reduces the chance of localised skin reactions building up over time.

Clean the skin with an alcohol swab and allow it to dry fully before injecting. Remove the pen cap, press the pen flat against the skin at a 90-degree angle, and hold the button down until you hear the click and see the grey plunger visible in the window, confirming the dose has been delivered. Keep the pen held against the skin for the full count your Patient Information Leaflet specifies before withdrawing. Dispose of the used needle in a sharps container immediately; never recap a used needle.

Storage remains the same too: keep the pen refrigerated at 2–8°C and consult your leaflet for the specific room-temperature window that applies if you need to travel. The NHS patient information for tirzepatide at nhs.uk/medicines/tirzepatide covers the essentials in plain language and is worth bookmarking alongside your leaflet.

Moving to 5 mg: what the prescriber is looking for first

If your prescriber has indicated a step up to 5 mg at your second pen, they will typically want to know that you tolerated the 2.5 mg phase reasonably well. That doesn't mean zero side effects, nausea, mild indigestion and changes in appetite are common in the first weeks and are described in detail in the guide to the 5 mg pen on this site. What your prescriber is really looking for is that those effects were manageable and that there are no clinical reasons to pause before increasing.

At nume, every repeat order is reviewed by a GPhC-registered Independent Prescriber before dispatch, a real clinician reads your update, not an automated system. If you're asking whether it's time to increase your strength, our page on your 2nd dose of Mounjaro is a helpful starting point before you raise it with the aftercare team. You can reach the team any day of the week.

For broader context on costs and what's included in a private prescription, the page on Mounjaro pricing in the UK is a useful reference. NICE's appraisal of tirzepatide (TA1026) also sets out the clinical criteria that guide prescriber decision-making at each stage of treatment, if you want the underlying framework your prescriber is working within.

When to contact your prescriber before injecting

There are specific situations where the right move is to speak to your clinical team before you administer your second dose, rather than after. These include: if you experienced severe or persistent nausea or vomiting during week one that hasn't fully settled; if you had significant stomach pain, particularly pain that spread toward your back; if your circumstances have changed (new medicines, a recent diagnosis, or a planned surgical procedure); or if the pen you've received carries a different strength from the one you expected.

None of these situations mean treatment has gone wrong. They mean your prescriber needs a brief update before confirming the right next step. The FAQ section covers some of the most common aftercare questions, and the contact page has direct routes to the clinical team. Mounjaro is a prescription medicine; the prescriber who reviewed your case is the appropriate person to advise on any change to your plan, including timing and strength. That's not a bureaucratic hurdle, it's the structure that keeps treatment safe.